Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Turkiye


Ocakli A. I., Ozyar-Kurtcu S. A., Uzun M., KAŞIKCI ÇAVDAR M., Telli-Dizman G., METAN G., ...Daha Fazla

INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, cilt.7, sa.2, ss.156-165, 2025 (ESCI, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.36519/idcm.2025.546
  • Dergi Adı: INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.156-165
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: The global effort to combat the COVID-19 pandemic requires a comprehensive assessment of vaccine efficacy, including both humoral and cellular immune responses. This study aimed to determine the effects of CoronaVac and BNT162b2 booster doses on quantitative immunoglobulin G (IgG) and interferon-gamma (IFN-gamma) responses of individuals primed with two doses of CoronaVac in Turkiye. Materials and Methods: This prospective cohort study included participants aged 18-59 years, without comorbidities, who were not under drug therapy and had no clinical history of COVID-19 and primed with CoronaVac. Participants were divided into three groups: Group 1 received a single CoronaVac booster, Group 2 received a single BNT162b2 booster, and Group 3 received two BNT162b2 boosters. Humoral immunity was assessed by the determination of IgG levels against the spike receptor-binding domain (RBD) protein of SARS-CoV-2, and cellular immunity was assessed by the IFN-gamma release assay. Results: The study included 48 participants. When the 6-12-month post-vaccination period was considered, the lowest quantitative IgG levels were detected in Group 1. Higher IgG levels were detected in Group 2 and Group 3, with Group 3 revealing the highest levels for both IgG and IFN-gamma responses. Although the differences between the IFN-gamma levels among the three groups were not statistically significant, the individuals boosted with the BNT162b2 demonstrated two- and three-fold higher levels compared to the homologous boosted individuals. The median IgG and IFN-gamma values were significantly higher in the younger participants compared to the older participants in Group 3. Conclusion: Our findings revealed that although homologous and heterologous boosting in inactivated vaccine-primed individuals provided effective humoral and cellular immunity, boosting with two doses of BNT162b2 should be prioritized since it exhibited a positive impact on both humoral and cellular immunity.